Characteristic | Conceived after AC (n=217) | Conceived spontaneously (n=1256) | p Value |
---|---|---|---|
Postnatal age at assessment, months | 35.7 (30.5–36.7) | 35.4 (30.7–36.8) | 0.68 |
Functional disability | |||
No apparent disability | 155 (71.4) | 866 (68.9) | 0.49 |
Mild | 21 (9.7) | 191 (15.2) | 0.04 |
Moderate | 25 (11.5) | 119 (9.5) | 0.43 |
Severe | 16 (7.4) | 80 (6.4) | 0.69 |
Moderate/severe disability | 41 (18.9) | 199 (15.9) | 0.32 |
In-vitro fertilisation* | 34/171 (19.9) | – | – |
Hyperovulation* | 7/46 (15.2) | – | – |
GQ/MDI | |||
−1 SD to −2 SD | 12 (5.5) | 72 (5.7) | 0.97 |
<−2 SD | 11 (5.1) | 57 (4.5) | 0.83 |
CP requiring walking aids | 20 (9.2) | 111 (8.8) | 0.96 |
Bilateral blindness | 1 (0.5) | 6 (0.5) | 1.00 |
Bilateral hearing loss | 10 (4.6) | 42 (3.3) | 0.46 |
Weight <10th percentile | 39 (18.0) | 263 (20.9) | 0.36 |
Height <10th percentile | 13 (6.0) | 153 (12.2) | 0.01 |
HC <10th percentile | 30 (13.8) | 279 (22.2) | 0.01 |
Data are presented as n (%) or median (IQR). Infants conceived spontaneously were set as a referent for OR and 95% CI calculation. In-vitro fertilisation includes gamete intra-fallopian transfer, zygote intra-fallopian transfer, etc. Hyperovulation includes any hormone therapy used to stimulate ovulation.
*The denominator is the number of infants in the corresponding subgroup.
AC, assisted conception; CP, cerebral palsy; GQ, general quotient; HC, head circumference; MDI, mental developmental index.